Amyotrophic lateral sclerosis: Difference between revisions
Tooba Kashif (talk | contribs) |
|||
| (9 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Amyotrophic lateral sclerosis}} | |||
{{CMG}}; {{AE}}{{M.B}} | |||
{{Infobox_Disease | {{Infobox_Disease | ||
| Name = Amyotrophic lateral sclerosis | | Name = Amyotrophic lateral sclerosis | ||
| Line 12: | Line 15: | ||
| MeshID = D000690 | | MeshID = D000690 | ||
}} | }} | ||
==[[Amyotrophic lateral sclerosis overview|Overview]]== | ==[[Amyotrophic lateral sclerosis overview|Overview]]== | ||
Amyotrophic Lateral Sclerosis is a chronic progressive neurological disease that affects both upper and lower motor neurons. It presents with muscle spasms, fasciculation, weakness and which could ultimately lead to muscles paralysis. ALS is diagnosed clinically, however additional testing with electromyography to confirm muscle denervation. Laboratory tests might be required to rule out other reversible causes of weakness. ALS has a poor prognosis with death usually due to respiratory complications with a median survival of 3-5 years. ALS is managed by a multidisciplinary care setting with fewer disease modifying agents to date. | |||
==[[Amyotrophic lateral sclerosis historical perspective|Historical Perspective]]== | ==[[Amyotrophic lateral sclerosis historical perspective|Historical Perspective]]== | ||
Amyotrophic Lateral Sclerosis was first described by French neurologist Jean-Martin Charcot in his Tuesday lectures in late 1860 and then a publication in 1874. He is also known as the ''' Father of Amyotrophic Lateral Sclerosis''' because of his devotion to the disease. He complied 50 years of previous work on muscle weakness. He was the first scientist to link the disease to its specific pathology. | |||
<ref name="pmid26515617">{{cite journal| author=Katz JS, Dimachkie MM, Barohn RJ| title=Amyotrophic Lateral Sclerosis: A Historical Perspective. | journal=Neurol Clin | year= 2015 | volume= 33 | issue= 4 | pages= 727-34 | pmid=26515617 | doi=10.1016/j.ncl.2015.07.013 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26515617 }} </ref> | |||
==[[Amyotrophic lateral sclerosis classification|Classification]]== | ==[[Amyotrophic lateral sclerosis classification|Classification]]== | ||
| Line 35: | Line 34: | ||
==[[Amyotrophic lateral sclerosis risk factors|Risk Factors]]== | ==[[Amyotrophic lateral sclerosis risk factors|Risk Factors]]== | ||
==[[Amyotrophic lateral sclerosis screening|Screening]]== | |||
==[[Amyotrophic lateral sclerosis natural history, complications and prognosis|Natural History, Complications and Prognosis]]== | ==[[Amyotrophic lateral sclerosis natural history, complications and prognosis|Natural History, Complications and Prognosis]]== | ||
==Diagnosis== | ==Diagnosis== | ||
[[Amyotrophic lateral sclerosis diagnostic evaluation|Diagnostic Evaluation]] | [[Amyotrophic lateral sclerosis history and symptoms|History and Symptoms]] | [[Amyotrophic lateral sclerosis physical examination|Physical Examination]] | [[Amyotrophic lateral sclerosis laboratory findings|Laboratory Findings]] | [[Amyotrophic lateral sclerosis diagnostic evaluation|Diagnostic Evaluation]] | [[Amyotrophic lateral sclerosis history and symptoms|History and Symptoms]] | [[Amyotrophic lateral sclerosis physical examination|Physical Examination]] | [[Amyotrophic lateral sclerosis laboratory findings|Laboratory Findings]] | [[Amyotrophic lateral sclerosis electrocardiogram|Electrocardiogram]] | [[Amyotrophic lateral sclerosis x ray|X Ray]] | [[Amyotrophic lateral sclerosis CT|CT]] | [[Amyotrophic lateral sclerosis MRI|MRI]] | [[Amyotrophic lateral sclerosis echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Amyotrophic lateral sclerosis other imaging findings|Other Imaging Findings]] | [[Amyotrophic lateral sclerosis other diagnostic studies|Other Diagnostic Studies]] | ||
==Treatment== | |||
[[Amyotrophic lateral sclerosis medical therapy|Medical Therapy]] | [[Amyotrophic lateral sclerosis surgery|Surgery]] | [[Amyotrophic lateral sclerosis primary prevention|Primary Prevention]] | [[Amyotrophic lateral sclerosis secondary prevention|Secondary Prevention]] | [[Amyotrophic lateral sclerosis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Amyotrophic lateral sclerosis future or investigational therapies|Future or Investigational Therapies]] | |||
==Case Studies== | |||
[[Amyotrophic lateral sclerosis case study|Case #1]] | |||
==Related Chapters== | ==Related Chapters== | ||
*[[Muscular Dystrophy Association]] | |||
*[[ALS Association]] | |||
*[[ALS Therapy Development Institute]] | |||
==References== | |||
{{reflist|2}} | |||
{{Diseases of the nervous system}} | {{Diseases of the nervous system}} | ||
[[Category:Neurology]] | |||
{{WS}} | |||
{{WH}} | {{WH}} | ||
Latest revision as of 11:32, 2 July 2021
|
Amyotrophic lateral sclerosis Microchapters |
|
Differentiating Amyotrophic lateral sclerosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Amyotrophic lateral sclerosis On the Web |
|
American Roentgen Ray Society Images of Amyotrophic lateral sclerosis |
|
Risk calculators and risk factors for Amyotrophic lateral sclerosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohsen Basiri M.D.
| Amyotrophic lateral sclerosis | |
 | |
|---|---|
| Stephen Hawking, a physicist who has ALS. | |
| ICD-10 | G12.2 |
| ICD-9 | 335.20 |
| OMIM | 105400 |
| DiseasesDB | 29148 |
| MedlinePlus | 000688 |
| MeSH | D000690 |
Overview
Amyotrophic Lateral Sclerosis is a chronic progressive neurological disease that affects both upper and lower motor neurons. It presents with muscle spasms, fasciculation, weakness and which could ultimately lead to muscles paralysis. ALS is diagnosed clinically, however additional testing with electromyography to confirm muscle denervation. Laboratory tests might be required to rule out other reversible causes of weakness. ALS has a poor prognosis with death usually due to respiratory complications with a median survival of 3-5 years. ALS is managed by a multidisciplinary care setting with fewer disease modifying agents to date.
Historical Perspective
Amyotrophic Lateral Sclerosis was first described by French neurologist Jean-Martin Charcot in his Tuesday lectures in late 1860 and then a publication in 1874. He is also known as the Father of Amyotrophic Lateral Sclerosis because of his devotion to the disease. He complied 50 years of previous work on muscle weakness. He was the first scientist to link the disease to its specific pathology. [1]
Classification
Pathophysiology
Causes
Differentiating Amyotrophic lateral sclerosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Evaluation | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
Related Chapters
References
- ↑ Katz JS, Dimachkie MM, Barohn RJ (2015). "Amyotrophic Lateral Sclerosis: A Historical Perspective". Neurol Clin. 33 (4): 727–34. doi:10.1016/j.ncl.2015.07.013. PMID 26515617.